TC-1 (Po)

Case ID:
Disclosure Date:
C03436: TC-1 (Po)

Technical Details:
This cell line "was developed to circumvent the confounding issue of negatively selecting nonessential tumor markers in cancer vaccine experiments. Primary lung epithelial cells from C57BL/6 mice were immortalized with HPV-16 E6 and E7 and then transformed with the activated ras oncogene. This transformation process mimics the natural sequence in the pathogenesis of cervical cancer in which HPV-16 plays a critical role in carcinogenesis".

Stage of Development:
TC-1 (Po) cell line may be used as a disease model for cervical cancer

Lin KY , et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56: 21-26, 1996. PubMed: 8548765
Chen CH , et al. Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. J. Hepatol. 33: 91-98, 2000. PubMed: 10905591
Ji H , et al. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer 78: 41-45, 1998. PubMed: 9724092
Patent Information:
For Information, Contact:
Christine Joseph
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum